Abstract
Introduction: Patients requiring major cardiovascular surgery are likely to be prescribed antiplatelet agents either alone or in combination. By virtue of antiplatelet agent effect, they can potentially increase bleeding complications, especially if used in combination. This article aims to review the evidence and make appropriate recommendations regarding these agents. Aspirin: 16 papers are reviewed which concern surgery whilst taking aspirin. The bulk of the evidence is from the coronary bypass setting. Clopidogrel: 14 papers are reviewed which concern surgery whilst taking clopidogrel. Dipyridamole: 2 papers are reviewed concerning dipyridamole. Cilostazol: No trials are available concerning surgery and cilostazol. Several relevant publications are reviewed. Conclusion: It is the recommendation of the authors that aspirin should usually be continued perioperatively, whilst clopidogrel should be stopped for seven days prior to surgery if at all possible.
Keywords: Aspirin, platelet aggregation inhibitors, cardiac surgical procedures, vascular surgical procedures, haemorrhage, post-operative complications
Current Drug Safety
Title: Oral Antiplatelet Agents and Bleeding Risk in Relation to Major Cardiovascular Surgery
Volume: 1 Issue: 3
Author(s): James McCaslin, Jonathan Smout, Patrick Kesteven and Gerard Stansby
Affiliation:
Keywords: Aspirin, platelet aggregation inhibitors, cardiac surgical procedures, vascular surgical procedures, haemorrhage, post-operative complications
Abstract: Introduction: Patients requiring major cardiovascular surgery are likely to be prescribed antiplatelet agents either alone or in combination. By virtue of antiplatelet agent effect, they can potentially increase bleeding complications, especially if used in combination. This article aims to review the evidence and make appropriate recommendations regarding these agents. Aspirin: 16 papers are reviewed which concern surgery whilst taking aspirin. The bulk of the evidence is from the coronary bypass setting. Clopidogrel: 14 papers are reviewed which concern surgery whilst taking clopidogrel. Dipyridamole: 2 papers are reviewed concerning dipyridamole. Cilostazol: No trials are available concerning surgery and cilostazol. Several relevant publications are reviewed. Conclusion: It is the recommendation of the authors that aspirin should usually be continued perioperatively, whilst clopidogrel should be stopped for seven days prior to surgery if at all possible.
Export Options
About this article
Cite this article as:
McCaslin James, Smout Jonathan, Kesteven Patrick and Stansby Gerard, Oral Antiplatelet Agents and Bleeding Risk in Relation to Major Cardiovascular Surgery, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934486
DOI https://dx.doi.org/10.2174/157488606777934486 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Neonatal Kidney: Implications for Drug Metabolism and Elimination
Current Drug Metabolism Identification and Usage of Fluorescent Probes as Nanoparticle Contrast Agents in Detecting Cancer
Current Pharmaceutical Design Extrasynaptic GABA<sub>A</sub> Receptors in the Brainstem and Spinal Cord: Structure and Function
Current Pharmaceutical Design Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension
Current Pharmaceutical Design Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Treatment of Pulmonary Thromboembolism in Patients with Systemic Blood Pressure Stability and Right Ventricular Dysfunction
Current Respiratory Medicine Reviews Putative Role for Apelin in Pressure/Volume Homeostasis and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections
Recent Patents on Nanotechnology Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology The Future of Interventional Management of Hypertension: Threats and Opportunities
Current Vascular Pharmacology Non-Invasive Methods and Techniques for Central Blood Pressure Estimation: Procedures, Validation, Reproducibility and Limitations
Current Pharmaceutical Design Serum Specific Vasopressin-Degrading Activity is Related to Blood Total Cholesterol Levels in Men but not in Women
Medicinal Chemistry Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Biochemistry, Biology, and Pharmacology of Cyclic Adenosine Diphosphoribose (cADPR)
Current Medicinal Chemistry Pathogenesis of Chronic “Cor pulmonale” in COPD
Current Respiratory Medicine Reviews